STAINES-UPON-THAMES, United Kingdom /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced creation of a Scientific Advisory Council (SAC) designed to provide external scientific guidance related to its strategy, research and development plans, and medical programs. Steven Romano, MD, Executive Vice President and Chief Scientific Officer, chaired today's inaugural meeting and expects the Council to contribute insights and external perspective to Mallinckrodt's Science and Technology organization, as well as serving as independent scientific advisors to MNK's Executive Committee and Board of Directors.
Joining Dr. Romano as charter members of the SAC are three leading experts in their respective fields, selected, in part, because of their experience and expertise in areas that are central to Mallinckrodt's current portfolio – namely, regenerative medicine, neonatal critical care and autoimmune and rare diseases. The first three external members include:
- Jörg C. Gerlach, MD, PhD, working as a Professor of Surgery and Bioengineering, McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Penn. Dr. Gerlach specializes in technologies for the clinical translation of stem cell biology and bioengineering research into cell-based therapies in regenerative medicine.
- Rashmin C. Savani, MD, ChB, Chief, Division of Neonatal-Perinatal Medicine, Associate Director, Center for Pulmonary and Vascular Biology, Professor and William Buchanan Chair of Pediatrics at University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Savani specializes in neonatal intensive care and lung disorders.
- Ulrich H. von Andrian, MD, PhD, Edward Mallinckrodt Jr. Chair of Immunopathology and Professor of Microbiology and Immunobiology, Harvard Medical School, Boston, Mass.; Director, Harvard Medical School Center for Immune Imaging. Dr. von Andrian, also the Program Leader in Basic Immunology for Ragon Institute of MGH1, MIT2 and Harvard, specializes in immunotherapy and autoimmune disorders.
"Mallinckrodt's Scientific Advisory Council reflects our ongoing commitment to being a premier, innovation-driven scientific organization, focused on developing pharmaceutical therapies that can improve outcomes for patients with severe and critical conditions," said Dr. Romano. "We are very pleased these exceptional physician scientists have agreed to join our SAC and we plan to add more members over time. Today's inaugural meeting was highly productive, and we look forward to ongoing collaboration with these experts."
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer
314-654-3638
daniel.speciale@mnk.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mnk.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mnk.com
